REVIEW PAPER
Interleukin-6 levels in the serum and saliva of patients with oral lichen planus compared with healthy controls: a meta-analysis study
Submission date: 2016-11-11
Final revision date: 2017-01-07
Acceptance date: 2017-02-20
Publication date: 2018-03-30
Cent Eur J Immunol 2018;43(1):103-108
KEYWORDS
ABSTRACT
Interleukin-6 (IL-6) is a cytokine that contributes to the pathogenesis of oral lichen planus (OLP). The aim of this meta-analysis study is the evaluation of IL-6 levels in the serum and saliva of patients with OLP compared with healthy controls. We searched the studies in 5 databases: PubMed/Medline, Scopus, ScienceDirect, Web of Science, and Cochrane Library, from 1983 to Oct 31, 2016. Eleven studies were analysed for the meta-analysis study. The reviewers independently evaluated the quality of each included study using the Newcastle-Ottawa Quality Assessment Scale (NOS). A random-effects meta-analysis, using Comprehensive Meta-Analysis software version 2.0, was used to reflect the variation in studies. Heterogeneity between estimates was evaluated by the Q and I2 statistics and for the Q statistic; heterogeneity was considered for p < 0.1. Eleven studies included 529 OLP patients and 333 healthy controls. The review identified two different biomaterials used for IL-6 assays: saliva and serum. The mean quality score of eleven studies was 7 (high quality). Estimates pooled from 6 studies showed significant high saliva IL-6 levels in OLP patients compared with healthy controls (the standardised difference in means (SDM) = 4.534, 95% CI = 1.915-7.153, p = 0.001). Also, estimates pooled from 7 studies showed significantly high serum IL-6 levels in OLP patients compared with healthy controls (SDM = 1.482, 95% CI = 0.524-2.439, p = 0.002). The higher levels of IL-6 in saliva compared with serum suggest that measurement of this marker in saliva may be more useful than serum for diagnostic and therapeutic aims.
REFERENCES (29)
1.
Abdel-Haq A, Kusnierz-Cabala B, Darczuk D, et al. (2014): Interleukin-6 and neopterin levels in the serum and saliva of patients with Lichen planus and oral Lichen planus. J Oral Pathol Med 43: 734-739.
2.
Gu GM, Martin MD, Darveau RP, et al. (2004): Oral and serum IL-6 levels in oral lichen planus patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98: 673-678.
3.
Mozaffari HR, Rahmani M, Rezaei F, et al. (2016): Evaluation of oral lichen planus frequency in patients referred to pathology centers of Kermanshah city, during 2008 to 2011. Sch J App Med Sci 4: 2200-2202.
4.
Sugerman PB, Savage NW, Walsh LJ, et al. (2002): The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 13: 350-365.
5.
Goel S, Marwah A, Kaushik S, et al. (2015): Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus. J Clin Exp Dent 7: e477-482.
6.
Dreuw A, Hermanns HM, Heise R, et al. (2005): Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts. J Invest Dermatol 124: 28-37.
7.
Hibi M, Nakajima K, Hirano T (1996): IL-6 cytokine family and signal transduction: a model of the cytokine system.
9.
Chang KP, Kao HK, Wu CC, et al. (2013): Pretreatment interleukin-6 serum levels are associated with patient survival for oral cavity squamous cell carcinoma. Otolaryngol Head Neck Surg 148: 786-791.
10.
Tamura S, Ouchi KF, Mori K, et al. (1995): Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin Cancer Res 1: 1353-1358.
11.
Hodge DR, Peng B, Cherry JC, et al. (2005): Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 65: 4673-4682.
12.
Nishimoto N (2010): Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther 87: 483-487.
13.
Jinno T, Kawano S, Maruse Y, et al. (2015): Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma. Oncol Rep 33: 2161-2168.
14.
Rhodus NL, Cheng B, Myers S, et al. (2005a): A comparison of the pro-inflammatory, NF-kappaB-dependent cytokines: TNF-αlpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol 114: 278-283.
15.
Rhodus NL, Cheng B, Bowles W, et al. (2006): Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone. Oral Dis 12: 112-116.
16.
Sun A, Wang J, Chia J, et al. (2005): Serum interleukin-8 level is a more sensitive marker than serum interleukin-6 level in monitoring the disease activity of oral lichen planus.
18.
Sun A, Chia JS, Chang YF, et al. (2002): Serum interleukin-6 level is a useful marker in evaluating therapeutic effects of levamisole and Chinese medicinal herbs on patients with oral lichen planus. J Oral Pathol Med 31: 196-203.
19.
Liu Y, Jin JQ, Yuan ZF, et al. (2011): [Levels of interlukin-6 and tumor necrosis factor- in saliva of patients with type 2 diabetes mellitus and oral lichen planus]. Beijing Da Xue Xue Bao 43: 596-599.
20.
Zhang Y, Lin M, Zhang S, et al. (2008): NF-kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: a study in an ethnic Chinese population.
22.
Rhodus NL, Cheng B, Myers S, et al. (2005b): The feasibility of monitoring NF-kappaB associated cytokines: TNF-αlpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog 44: 77-82.
23.
Kaur J, Jacobs R (2015): Proinflammatory cytokine levels in oral lichen planus, oral leukoplakia, and oral submucous fibrosis. J Korean Assoc Oral Maxillofac Surg 41: 171-175.
24.
Yamamoto T, Yoneda K, Ueta E, et al. (1994): Serum cytokines, interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in oral disorders. Oral Surg Oral Med Oral Pathol 78: 727-735.
25.
Zheng Z, Zhang L, Zhu T, et al. (2016): Peripheral brain-derived neurotrophic factor in autism spectrum disorder: a systematic review and meta-analysis. Sci Rep 6: 31241.
26.
Postal M, Appenzeller S (2011): The role of Tumor Necrosis Factor-alpha (TNF-αlpha) in the pathogenesis of systemic lupus erythematosus. Cytokine 56: 537-543.
27.
Eppel W, Worda C, Frigo P, et al. (2000): The influence of cotinine on interleukin 6 expression in smokers with cervical preneoplasia. Acta Obstet Gynecol Scand 79: 1105-1111.
28.
Brailo V, Vucicevic-Boras V, Lukac J, et al. (2012): Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer. Med Oral Patol Oral Cir Bucal 17: e10-15.
29.
Pezelj-Ribaric S, Prso IB, Abram M, et al. (2004): Salivary levels of tumor necrosis factor-alpha in oral lichen planus. Mediators Inflamm 13: 131-133.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
